Healx is a pioneering biotech company dedicated to accelerating the discovery and development of treatments for rare diseases. Founded in 2014 by Dr. Tim Guilliams, Dr. David Brown, and patient advocate Nick Sireau, Healx combines the powerful capabilities of artificial intelligence with innovative drug redevelopment strategies. Their mission is centered around the belief that every rare disease patient deserves accessible treatment. Healx has created a next-generation AI platform that identifies novel connections between existing drugs and diseases, streamlining the transition of potential therapies from the lab to clinical trials.

The company is committed to supporting the rare disease community through volunteering and partnerships, ensuring that patient needs drive their projects. Healx actively engages in various therapeutic areas, including oncology and neurofibromatosis, and aims to address the unique challenges faced by these patient groups. With over $100 million raised and a team of passionate experts, Healx is positioned at the forefront of innovation, dedicated to transforming lives through impactful healthcare solutions.